Julie St-Pierre (@drjuliestpierre) 's Twitter Profile
Julie St-Pierre

@drjuliestpierre

Professeure MD PhD FAHA. Auteure de Redonner la santé à toute la famille. Chercheure et experte en obésité des jeunes Canada, USA, Europe McGill University

ID: 1600465854872883200

linkhttp://maisondesanteprevention.com calendar_today07-12-2022 12:22:59

542 Tweet

336 Takipçi

232 Takip Edilen

Julie St-Pierre (@drjuliestpierre) 's Twitter Profile Photo

Science must go on 🇨🇦🇺🇸 and let’s stay united. We are pleased, as Canadian clinical experts, to be invited in USA to show proofs that children and adolescents living with obesity and social vulnerabilities can change their lifestyle, reduce clinical obesity, and be successful

Julie St-Pierre (@drjuliestpierre) 's Twitter Profile Photo

Congratulations to Marie Cyrenne-Dussault from Laval University 🇨🇦 As a PhD candidate, you did an amazing poster presentation American Heart Association #EpiLifestyle25 Free access to multidisciplinary care in pediatric obesity enables lifestyle changes and will save lives! ❤️

Congratulations to Marie Cyrenne-Dussault from Laval University 🇨🇦

As a PhD candidate, you did an amazing poster presentation <a href="/American_Heart/">American Heart Association</a> 
#EpiLifestyle25

Free access to multidisciplinary care in pediatric obesity enables lifestyle changes and will save lives! ❤️
Julie St-Pierre (@drjuliestpierre) 's Twitter Profile Photo

Innovators in Workplace Well-Being: The Top Healthcare Leaders to Watch in 2025 Thank you Global Healthcare Magazine for this nomination. My story is one of many contributing to a healthier tomorrow. Let's strengthen global cooperation to promote the health and well-being of all.

World Obesity (@worldobesity) 's Twitter Profile Photo

🧒🏽 By 2035, 750 million children will be living with overweight or obesity. That’s 2 in 5 kids at increased risk of early NCDs like heart disease and diabetes. But the path to prevention starts early: 🤱🏽 Promoting and supporting breastfeeding 👩🏽‍⚕️ Ensuring maternal health and

🧒🏽 By 2035, 750 million children will be living with overweight or obesity.

That’s 2 in 5 kids at increased risk of early NCDs like heart disease and diabetes.

But the path to prevention starts early:
🤱🏽 Promoting and supporting breastfeeding
👩🏽‍⚕️ Ensuring maternal health and
Julie St-Pierre (@drjuliestpierre) 's Twitter Profile Photo

Read the full magazine here ❤️ 👇🏻 digital.globalhealthcaremagazine.com/2025/Pediatric… Thanks Global Healthcare magazine for this kind selection.

Read the full magazine here ❤️

👇🏻

digital.globalhealthcaremagazine.com/2025/Pediatric…

Thanks Global Healthcare magazine for this kind selection.
Julie St-Pierre (@drjuliestpierre) 's Twitter Profile Photo

🎉 New Guideline 🥳 Happy to share our 2025 Canadian Guidelines. Management of obesity in children. Learn our recommendations regarding: - Lifestyle 🏃‍♀️🍎 - Pharmacotherapy 💊 - Bariatric surgery 👩🏼‍⚕️ cmaj.ca/content/197/14…

FMSQ (@fmsq) 's Twitter Profile Photo

Non, M. Dubé, les médecins spécialistes ne quittent pas le travail à 16h le vendredi. Nous n'avons qu'un seul objectif: soigner nos patients, et ce, peu importe l'heure ou le jour de la semaine. Ce n'est pas d'un projet de loi que les patients ont besoin, mais d'un système bien

Julie St-Pierre (@drjuliestpierre) 's Twitter Profile Photo

When a pediatric multidisciplinary team makes a difference in children’s lives. #approach180 #obesity #bloodpressure #HealthyLiving cdnsciencepub.com/doi/10.1139/ap…

When a pediatric multidisciplinary team makes a difference in children’s lives.

#approach180 #obesity #bloodpressure 
#HealthyLiving 

cdnsciencepub.com/doi/10.1139/ap…
GoggleDocs (@goggledocs) 's Twitter Profile Photo

#ADA2025: NA-931 – Oral Quadruple Receptor Agonist 🚀 Targets GLP-1, GIP, glucagon & IGF-1 – aiming for fat loss and lean mass preservation 🔬 Phase 2, 13-week RCT (n=125; BMI ≥30 or ≥27 + comorbidity) 🧍 WL at 13 wks:  ⤵️ 11.9% at 150 mg  ⤵️ 9.1% at 100 mg  vs⤵️ 1.8% (pbo)

#ADA2025: NA-931 – Oral Quadruple Receptor Agonist 🚀

Targets GLP-1, GIP, glucagon &amp; IGF-1 – aiming for fat loss and lean mass preservation

🔬 Phase 2, 13-week RCT (n=125; BMI ≥30 or ≥27 + comorbidity)

🧍 WL at 13 wks:
 ⤵️ 11.9% at 150 mg
 ⤵️ 9.1% at 100 mg
 vs⤵️ 1.8% (pbo)